Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

Rhea-AI Summary

Disc Medicine (NASDAQ:IRON) will present Phase 1b clinical data for DISC-0974 at the 2025 American Society of Nephrology Kidney Week in Houston, Nov 6-9, 2025.

The poster (Abstract 4351248, Poster SA-PO1183) is scheduled for Nov 8, 2025 at 10:00 am CST (11:00 am EST) with Pablo Pergola, M.D., Ph.D. as presenting author. The randomized, double-blind, placebo-controlled Phase 1b study evaluates single ascending and multiple doses in nondialysis-dependent CKD patients with anemia, reporting safety, tolerability, PK, and pharmacodynamic markers including hepcidin, iron, and hematologic parameters. The abstract is available on the ASN Kidney Week website.

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will present clinical data as a poster presentation at the upcoming 2025 American Society of Nephrology (ASN) Kidney Week, which will be held in Houston, TX on November 6-9, 2025.

“We look forward to returning to Kidney Week this year, where we will provide an update from our Phase 1b study of DISC-0974 in NDD-CKD patients with anemia,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “At the meeting, we plan to share data from all single and multiple-dose cohorts, including safety and tolerability, PK and pharmacodynamic markers.”

The poster presentation will provide a data update from the Phase 1b, randomized, placebo-controlled study of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia. This study was designed to assess the safety, tolerability and pharmacokinetics of single ascending and multiple doses of DISC-0974, as well as measures of pharmacodynamic activity, including changes to hepcidin, iron, and hematologic parameters.

The abstract is now available through the ASN Kidney Week conference website. Pursuant to Disc Medicine practice, the abstract published today contains previously presented data, and new data and analyses are reserved for presentation at the conference.

Details of Presentation:

Abstract Number: 4351248
Title: A Phase 1b, Double-Blind, Placebo-Controlled Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Nondialysis-Dependent CKD and Anemia
Date / Time: Saturday, November 8, 10:00 am CST / 11:00 am EST
Poster Number: SA-PO1183
Presenting Author: Pablo Pergola, M.D., Ph.D.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Disc Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding: the projected timeline for the presentation of DISC-0974 data. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Disc’s Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.

Media Contact

Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact

Christina Tartaglia
Precision AQ
Christina.tartaglia@precisionaq.com

FAQ

When will Disc Medicine (IRON) present DISC-0974 data at ASN Kidney Week 2025?

Disc Medicine will present on November 8, 2025 at 10:00 am CST (11:00 am EST) as Poster SA-PO1183.

What Phase is the DISC-0974 study being presented by IRON at ASN 2025?

The presentation covers a Phase 1b randomized, double-blind, placebo-controlled study in NDD-CKD patients with anemia.

What endpoints will IRON report for DISC-0974 at the conference?

The poster will report safety, tolerability, pharmacokinetics, and pharmacodynamic markers including hepcidin, iron, and hematologic parameters.

Where can investors access the DISC-0974 abstract for ASN Kidney Week 2025?

The abstract (Number 4351248) is available on the ASN Kidney Week conference website.

Who is the presenting author for Disc Medicine's DISC-0974 poster (IRON)?

The presenting author is Pablo Pergola, M.D., Ph.D. for Poster SA-PO1183.

What patient population was studied in IRON's DISC-0974 Phase 1b trial?

The study enrolled patients with nondialysis-dependent chronic kidney disease (NDD-CKD) and anemia.